Cox regression univariable and multivariable analysis for OS
| Covariate . | Univariate analysis (HR, 95% CI)∗ . | P value . | Multivariate analysis (HR, 95% CI) . | P value . |
|---|---|---|---|---|
| Age (y) | 1.06 (1.03-1.10) | <.001 | 1.07 (1.03-1.11) | .002 |
| Male sex | 0.90 (0.59-1.36) | .61 | Not included | |
| Prior MDS and MDS/MPN | 3.74 (1.98-7.07) | <.001 | 2.87 (1.47-5.61) | .002 |
| Therapy-related disease | 2.31 (1.30-4.10) | .004 | 1.81 (1.00-3.27) | .050 |
| HMA/VEN vs IC | 1.61 (1.04-2.50) | .034 | 0.71 (0.40-1.27) | .25 |
| Abnormal cytogenetics | 2.17 (1.29-3.66) | .003 | 1.91 (1.09-3.38) | .025 |
| CEBPA mutation | 1.16 (0.60-2.23) | .66 | Not included | |
| DNMT3A mutation | 0.95 (0.63-1.44) | .82 | Not included | |
| IDH1 mutation | 0.62 (0.33-1.17) | .14 | Not included | |
| IDH2 mutation | 0.89 (0.53-1.50) | .67 | Not included | |
| KRAS mutation | 0.60 (0.19-1.91) | .39 | Not included | |
| NRAS mutation | 0.95 (0.49-1.84) | .88 | Not included | |
| PTPN11 mutation | 0.91 (0.51-1.62) | .75 | Not included | |
| SF3B1 mutation | 2.35 (1.24-4.45) | .009 | Not included | |
| SRSF2 mutation | 1.31 (0.69-2.48) | .41 | Not included | |
| TET2 mutation | 1.21 (0.78-1.87) | .39 | Not included | |
| WT1 mutation | 0.65 (0.26-1.61) | .35 | Not included | |
| FLT3-ITD mutation | 1.63 (1.07-2.49) | .024 | 1.72 (1.12-2.64) | .013 |
| FLT3-TKD mutation | 1.04 (0.61-1.76) | .89 | Not included | |
| Splicing mutation†,‡ | 1.77 (1.04-3.00) | .036 | Not included | |
| Allo-SCT (time-varying variable) | 0.89 (0.54-1.46) | .64 | Not included |
| Covariate . | Univariate analysis (HR, 95% CI)∗ . | P value . | Multivariate analysis (HR, 95% CI) . | P value . |
|---|---|---|---|---|
| Age (y) | 1.06 (1.03-1.10) | <.001 | 1.07 (1.03-1.11) | .002 |
| Male sex | 0.90 (0.59-1.36) | .61 | Not included | |
| Prior MDS and MDS/MPN | 3.74 (1.98-7.07) | <.001 | 2.87 (1.47-5.61) | .002 |
| Therapy-related disease | 2.31 (1.30-4.10) | .004 | 1.81 (1.00-3.27) | .050 |
| HMA/VEN vs IC | 1.61 (1.04-2.50) | .034 | 0.71 (0.40-1.27) | .25 |
| Abnormal cytogenetics | 2.17 (1.29-3.66) | .003 | 1.91 (1.09-3.38) | .025 |
| CEBPA mutation | 1.16 (0.60-2.23) | .66 | Not included | |
| DNMT3A mutation | 0.95 (0.63-1.44) | .82 | Not included | |
| IDH1 mutation | 0.62 (0.33-1.17) | .14 | Not included | |
| IDH2 mutation | 0.89 (0.53-1.50) | .67 | Not included | |
| KRAS mutation | 0.60 (0.19-1.91) | .39 | Not included | |
| NRAS mutation | 0.95 (0.49-1.84) | .88 | Not included | |
| PTPN11 mutation | 0.91 (0.51-1.62) | .75 | Not included | |
| SF3B1 mutation | 2.35 (1.24-4.45) | .009 | Not included | |
| SRSF2 mutation | 1.31 (0.69-2.48) | .41 | Not included | |
| TET2 mutation | 1.21 (0.78-1.87) | .39 | Not included | |
| WT1 mutation | 0.65 (0.26-1.61) | .35 | Not included | |
| FLT3-ITD mutation | 1.63 (1.07-2.49) | .024 | 1.72 (1.12-2.64) | .013 |
| FLT3-TKD mutation | 1.04 (0.61-1.76) | .89 | Not included | |
| Splicing mutation†,‡ | 1.77 (1.04-3.00) | .036 | Not included | |
| Allo-SCT (time-varying variable) | 0.89 (0.54-1.46) | .64 | Not included |
All variables with P value < .1 in the univariate model were included in the multivariable model, which was refined using backward selection. In the multivariable model, bold values show covariates identified as significant (P < .05).
IC, intensive induction chemotherapy; TKD, tyrosine kinase domain.
Only variables present in 5% of patients included in univariate analysis.
Splicing mutations include SF3B1, SRSF2, U2AF1, and ZRSR2.
Excluded from the multivariable model because of potential colinearity.